BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 27, 2026
Home
»
Authors
»
Aaron Lorenzo
Articles by Aaron Lorenzo
Keryx Has Cash For Three Years After $15M Private Placement
Nov. 19, 2003
By
Aaron Lorenzo
Keryx Has Cash For Three Years After $15M Private Placement
Nov. 19, 2003
By
Aaron Lorenzo
Amgen Reports Phase III Data On Cinacalcet, Gets Priority Review
Nov. 18, 2003
By
Aaron Lorenzo
MGI In-Licenses Further Rights To Approved Cancer Drug Aloxi
Nov. 18, 2003
By
Aaron Lorenzo
Amgen Reports Phase III Data On Cinacalcet, Gets Priority Review
Nov. 18, 2003
By
Aaron Lorenzo
MGI In-Licenses Further Rights To Approved Cancer Drug Aloxi
Nov. 18, 2003
By
Aaron Lorenzo
YM Licenses European Rights To Cancer Drug In $30M Deal
Nov. 13, 2003
By
Aaron Lorenzo
YM Licenses European Rights To Cancer Drug In $30M Deal
Nov. 13, 2003
By
Aaron Lorenzo
Aderis Drug Slows Ventricular Rate In Atrial Fibrillation Study
Nov. 12, 2003
By
Aaron Lorenzo
Aradigm Adds To Cash Position With $13.5M Private Placement
Nov. 12, 2003
By
Aaron Lorenzo
Previous
1
2
…
164
165
166
167
168
169
170
171
172
…
237
238
Next
